University Of Cologne
Clinical trials sponsored by University Of Cologne, explained in plain language.
-
New hope for myeloma patients: daratumumab combo shows promise without transplant
Disease control OngoingThis study tests a drug combination including daratumumab as the first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. After initial therapy, patients receive maintenance treatment until the disease returns, then they are re-treated with d…
Phase: PHASE2 • Sponsor: University of Cologne • Aim: Disease control
Last updated May 17, 2026 08:05 UTC
-
Real-World data on caplacizumab for rare blood disorder
Knowledge-focused OngoingThis study reviews medical records of 350 adults with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab. Researchers want to see how doctors decide to use the drug, how well it works outside of clinical trials, and what factors predict complications. T…
Sponsor: University of Cologne • Aim: Knowledge-focused
Last updated May 08, 2026 12:01 UTC